JacobP.LaubachMD

PubMed

• Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethas...
  Rebecca Silbermann, Jacob Laubach, Jonathan L Kaufman, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Luciano J Costa, Larry D Anderson Jr, Nitya Nathwa...> ;American Journal of Hematology. 2024 Apr 15
• Mezigdomide-A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma.
  Monique A Hartley-Brown, Clifton C Mo, Omar Nadeem, Shonali Midha, Jacob P Laubach, Paul G Richardson> ;Cancers. 2024 Mar 15
• A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma.
  Shonali Midha, Monique A Hartley-Brown, Clifton C Mo, Shahrier Hossain, Omar Nadeem, Elizabeth K O'Donnell, Giada Bianchi, Adam S Sperling, Jacob P Laubach, Paul G Ric...> ;Expert Opinion on Drug Safety. 2023 Nov 28
• Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma.
  Paul G Richardson, Brian G Durie, Laura Rosiñol, Maria-Victoria Mateos, Angela Dispenzieri, Philippe Moreau, Shaji Kumar, Noopur Raje, Nikhil Munshi, Jacob P Laubach, ...> ;Haematologica. 2023 Nov 1
• 3 citations
  Selinexor: Targeting a novel pathway in multiple myeloma.
  Clifton C Mo, Andrew J Yee, Shonali Midha, Monique A Hartley-Brown, Omar Nadeem, Elizabeth K O'Donnell, Giada Bianchi, Adam S Sperling, Jacob P Laubach, Paul G Richardson> ;Ejhaem. 2023 Aug 1
• 13 citations
  Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER ...
  Saurabh Chhabra, Natalie Callander, Nicole L Watts, Luciano J Costa, Bicky Thapa, Jonathan L Kaufman, Jacob Laubach, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, ...> ;Transplantation and Cellular Therapy. 2023 Mar 1
• 8 citations
  Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.
  Romanos Sklavenitis-Pistofidis, Michelle P Aranha, Robert A Redd, Joanna Baginska, Nicholas J Haradhvala, Margaret Hallisey, Ankit K Dutta, Alexandra Savell, Shohreh V...> ;Cancer Cell. 2022 Nov 14
• 8 citations
  Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.
  Douglas W Sborov, Muhamed Baljevic, Brandi Reeves, Jacob Laubach, Yvonne A Efebera, Cesar Rodriguez, Luciano J Costa, Ajai Chari, Rebecca Silbermann, Sarah A Holstein,...> ;British Journal of Haematology. 2022 Nov 1
• 4 citations
  Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma.
  Elizabeth K O'Donnell, Yael N Shapiro, Andrew J Yee, Omar Nadeem, Jacob P Laubach, Andrew R Branagan, Kenneth C Anderson, Clifton C Mo, Nikhil C Munshi, Irene M Ghobri...> ;Blood Advances. 2022 Sep 13
• 128 citations
  Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
  Paul G Richardson, Susanna J Jacobus, Edie A Weller, Hani Hassoun, Sagar Lonial, Noopur S Raje, Eva Medvedova, Philip L McCarthy, Edward N Libby, Peter M Voorhees, Rob...> ;The New England Journal of Medicine. 2022 Jul 14
• 1 citations
  Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma.
  Matthew Ho, Maria Moscvin, Soon Khai Low, Benjamin Evans, Sara Close, Robert Schlossman, Jacob Laubach, Claudia Paba Prada, Brett Glotzbecker, Paul G Richardson, Giada...> ;Leukemia & Lymphoma. 2022 Oct 1
• 23 citations
  Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, mu...
  Meletios A Dimopoulos, Paul G Richardson, Nizar J Bahlis, Sebastian Grosicki, Michele Cavo, Meral Beksaç, Wojciech Legieć, Anna M Liberati, Hartmut Goldschmidt, Andrew...> ;The Lancet. Haematology. 2022 Jun 1
• 12 citations
  Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma.
  Elizabeth K O'Donnell, Yael N Shapiro, Andrew J Yee, Omar Nadeem, Bonnie Y Hu, Jacob P Laubach, Andrew R Branagan, Kenneth C Anderson, Clifton C Mo, Nikhil C Munshi, I...> ;Cancer. 2022 May 15
• 3 citations
  Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma.
  Peter O'Gorman, Jacob P Laubach, Michael E O'Dwyer, Janusz Krawczyk, Andrew J Yee, Oonagh Gilligan, Mary R Cahill, Jacalyn Rosenblatt, John Quinn, Philip T Murphy, Hei...> ;American Journal of Hematology. 2022 May 1
• 13 citations
  Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma.
  Johannes M Waldschmidt, Andrew J Yee, Tushara Vijaykumar, Ricardo A Pinto, Julia Frede, Praveen Anand, Giada Bianchi, Guangwu Guo, Sayalee Potdar, Charles Seifer, Moni...> ;Leukemia. 2022 Apr 1
• 17 citations
  Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
  Saad Z Usmani, Hareth Nahi, Wojciech Legiec, Sebastian Grosicki, Vladimir Vorobyev, Ivan Spicka, Vania Hungria, Sibirina Korenkova, Nizar J Bahlis, Max Flogegard, Joan...> ;Haematologica. 2022 Oct 1
• 6 citations
  Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study.
  Alessandra Larocca, Xavier Leleu, Cyrille Touzeau, Joan Bladé, Agne Paner, Maria-Victoria Mateos, Michele Cavo, Christopher Maisel, Adrian Alegre, Albert Oriol, Anasta...> ;British Journal of Haematology. 2021 Oct 21
• 18 citations
  Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma
  Julia Frede, Praveen Anand, Noori Sotudeh, Ricardo A. Pinto, Monica S. Nair, Hannah T. Stuart, Andrew Yee, Tushara Vijaykumar, Johannes M. Waldschmidt, Sayalee Potdar,...> ;Nature Cell Biology. 2021 Oct 21
• 14 citations
  A phase I/II study of ixazomib, pomalidomide and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma. (Alliance A061202)
  Peter M. Voorhees, Vera J. Suman, Sascha A. Tuchman, Jacob P. Laubach, Hani Hassoun, Yvonne A. Efebera, Flora Mulkey, Misty Bova-Solem, Katelyn Santo, Destin Carlisle,...> ;American Journal of Hematology. 2021 Sep 24
• 13 citations
  Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma.
  Johannes M. Waldschmidt, Jake A. Kloeber, Praveen Anand, Julia Frede, Antonis Kokkalis, Valeriya Dimitrova, Sayalee Potdar, Monica S. Nair, Tushara Vijaykumar, Nam Gyu...> ;Clinical Cancer Research. 2021 Sep 10
• 7 citations
  A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.
  Karthik Ramasamy, Ajay K. Nooka, Hang Quach, Myo Htut, Rakesh Popat, Michaela Liedtke, Sascha A. Tuchman, Jacob P. Laubach, Cristina Gasparetto, Asher Chanan-Khan, Mar...> ;Blood Cancer Journal. 2021 Sep 3
• 6 citations
  Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma.
  Jesus G. Berdeja, Jacob P. Laubach, Joshua Richter, Steve Stricker, Andrew Spencer, Paul G. Richardson, Ajai Chari> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Nov 1
• 42 citations
  Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Mye...
  Paul G. Richardson, Shaji Kumar, Tamás Masszi, Norbert Grzasko, Nizar J. Bahlis, Markus Hansson, Luděk Pour, Irwindeep Sandhu, Peter Ganly, Bartrum W Baker, Sharon Jac...> ;Journal of Clinical Oncology. 2021 Jun 11
• 11 citations
  Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma
  Saad Z. Usmani, Chatchada Karanes, William I. Bensinger, Anita D'Souza, Noopur Raje, Sascha A. Tuchman, Douglas W. Sborov, Jacob P. Laubach, Giada Bianchi, Dheepak Kan...> ;Leukemia. 2021 May 28
• 106 citations
  Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
  Philippe Moreau, Shaji Kumar, Jesus San Miguel, Faith E. Davies, Elena Zamagni, Nizar J. Bahlis, Heinz Ludwig, Joseph R. Mikhael, Evangelos Terpos, Fredrik Schjesvold,...> ;The Lancet. Oncology. 2021 Mar 1
• Join now to see all

Abstracts/Posters

• Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins
  Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple Myeloma
  Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
  Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma
  Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
  Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
  Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refr...
  Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy
  Jacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Improving Rates of Venous Thromboembolism Prophylaxis in Multiple Myeloma Patients on Immunomodulatory Drugs 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoprotein... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Mult... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Evaluation of Re-Intensification of Daratumumab to Weekly or Biweekly Dosing Schedule 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Debate: Should Everyone Receive Monoclonal Antibodies in First Relapse? Yes 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
• Join now to see all